• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纤溶酶原激活物抑制剂-1反应中心的饱和诱变

Saturation mutagenesis of the plasminogen activator inhibitor-1 reactive center.

作者信息

Sherman P M, Lawrence D A, Yang A Y, Vandenberg E T, Paielli D, Olson S T, Shore J D, Ginsburg D

机构信息

Department of Human Genetics, Howard Hughes Medical Institute, University of Michigan Medical School, Ann Arbor 48109.

出版信息

J Biol Chem. 1992 Apr 15;267(11):7588-95.

PMID:1559996
Abstract

Plasminogen activator inhibitor-1 (PAI-1) is a specific inhibitor of the serine proteases tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). To systematically investigate the roles of the reactive center P1 and P1' residues in PAI-1 function, saturation mutagenesis was utilized to construct a library of PAI-1 variants. Examination of 177 unique recombinant proteins indicated that a basic residue was required at P1 for significant inhibitory activity toward uPA, whereas all substitutions except proline were tolerated at P1'. P1Lys variants exhibited lower inhibition rate constants and greater sensitivity to P1' substitutions than P1Arg variants. Alterations at either P1 or P1' generally had a larger effect on the inhibition of tPA. A number of variants that were relatively specific for either uPA or tPA were identified. P1Lys-P1'Ala reacted 40-fold more rapidly with uPA than tPA, whereas P1Lys-P1'Trp showed a 6.5-fold preference for tPA. P1-P1' variants containing additional mutations near the reactive center demonstrated only minor changes in activity, suggesting that specific amino acids in this region do not contribute significantly to PAI-1 function. These findings have important implications for the role of reactive center residues in determining serine protease inhibitor (serpin) function and target specificity.

摘要

纤溶酶原激活物抑制剂-1(PAI-1)是丝氨酸蛋白酶组织型纤溶酶原激活物(tPA)和尿激酶型纤溶酶原激活物(uPA)的特异性抑制剂。为了系统研究反应中心P1和P1'残基在PAI-1功能中的作用,利用饱和诱变构建了PAI-1变体文库。对177种独特重组蛋白的检测表明,P1位点需要一个碱性残基才能对uPA具有显著的抑制活性,而P1'位点除脯氨酸外的所有取代均可耐受。与P1Arg变体相比,P1Lys变体表现出更低的抑制速率常数和对P1'取代更高的敏感性。P1或P1'位点的改变通常对tPA的抑制作用影响更大。鉴定出了一些对uPA或tPA具有相对特异性的变体。P1Lys-P1'Ala与uPA的反应速度比与tPA的反应速度快40倍,而P1Lys-P1'Trp对tPA的偏好性为6.5倍。在反应中心附近含有额外突变的P1-P1'变体仅表现出轻微的活性变化,这表明该区域的特定氨基酸对PAI-1功能的贡献不大。这些发现对于反应中心残基在确定丝氨酸蛋白酶抑制剂(serpin)功能和靶标特异性中的作用具有重要意义。

相似文献

1
Saturation mutagenesis of the plasminogen activator inhibitor-1 reactive center.纤溶酶原激活物抑制剂-1反应中心的饱和诱变
J Biol Chem. 1992 Apr 15;267(11):7588-95.
2
Identification of tissue-type plasminogen activator-specific plasminogen activator inhibitor-1 mutants. Evidence that second sites of interaction contribute to target specificity.组织型纤溶酶原激活物特异性纤溶酶原激活物抑制剂-1突变体的鉴定。相互作用的第二位点有助于靶标特异性的证据。
J Biol Chem. 1995 Apr 21;270(16):9301-6. doi: 10.1074/jbc.270.16.9301.
3
Mutational and immunochemical analysis of plasminogen activator inhibitor 1.
J Biol Chem. 1990 Oct 25;265(30):18379-85.
4
Sequence requirements in the reactive-center loop of plasminogen-activator inhibitor-1 for recognition of plasminogen activators.纤溶酶原激活物抑制剂-1反应中心环中用于识别纤溶酶原激活物的序列要求。
Eur J Biochem. 1996 Apr 1;237(1):180-7. doi: 10.1111/j.1432-1033.1996.0180n.x.
5
Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties.蛋白质辅因子对丝氨酸蛋白酶抑制剂特异性的改变。纤连蛋白赋予纤溶酶原激活物抑制剂1凝血酶抑制特性。
J Biol Chem. 1990 Aug 5;265(22):13029-35.
6
The inhibition mechanism of serpins. Evidence that the mobile reactive center loop is cleaved in the native protease-inhibitor complex.丝氨酸蛋白酶抑制剂(serpins)的抑制机制。有证据表明,在天然蛋白酶-抑制剂复合物中,可移动的反应中心环被切割。
J Biol Chem. 1995 Dec 15;270(50):29652-5. doi: 10.1074/jbc.270.50.29652.
7
Structure-function studies of the SERPIN plasminogen activator inhibitor type 1. Analysis of chimeric strained loop mutants.
J Biol Chem. 1990 Nov 25;265(33):20293-301.
8
A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.尿激酶生长因子结构域与2型纤溶酶原激活物抑制剂的杂合蛋白可抑制尿激酶活性,并与尿激酶受体结合。
Eur J Biochem. 1992 Jul 1;207(1):177-83. doi: 10.1111/j.1432-1033.1992.tb17035.x.
9
A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism.纤溶酶原激活物抑制剂-1的荧光探针研究。反应中心环插入的证据及其在抑制机制中的作用。
J Biol Chem. 1995 Mar 10;270(10):5395-8. doi: 10.1074/jbc.270.10.5395.
10
Serpin reactive center loop mobility is required for inhibitor function but not for enzyme recognition.丝氨酸蛋白酶抑制剂反应中心环的流动性是抑制剂功能所必需的,但不是酶识别所必需的。
J Biol Chem. 1994 Nov 4;269(44):27657-62.

引用本文的文献

1
High-throughput amino acid-level characterization of the interactions of plasminogen activator inhibitor-1 with variably divergent proteases.纤溶酶原激活物抑制剂-1与可变差异蛋白酶相互作用的高通量氨基酸水平表征
Protein Sci. 2025 Apr;34(4):e70088. doi: 10.1002/pro.70088.
2
Deep mutational scanning and massively parallel kinetics of plasminogen activator inhibitor-1 functional stability to probe its latency transition.深突变扫描和纤溶酶原激活物抑制剂-1 功能稳定性的大规模并行动力学,以探索其潜伏态转变。
J Biol Chem. 2022 Dec;298(12):102608. doi: 10.1016/j.jbc.2022.102608. Epub 2022 Oct 17.
3
Deep mutational scanning of the plasminogen activator inhibitor-1 functional landscape.
深突变扫描纤溶酶原激活物抑制剂-1 的功能图谱。
Sci Rep. 2021 Sep 22;11(1):18827. doi: 10.1038/s41598-021-97871-7.
4
Single fluorescence probes along the reactive center loop reveal site-specific changes during the latency transition of PAI-1.沿着反应中心环的单个荧光探针揭示了纤溶酶原激活物抑制剂-1潜伏转变过程中的位点特异性变化。
Protein Sci. 2016 Feb;25(2):487-98. doi: 10.1002/pro.2839. Epub 2015 Nov 25.
5
Encephalopathy with neuroserpin inclusion bodies presenting as progressive myoclonus epilepsy and associated with a novel mutation in the Proteinase Inhibitor 12 gene.伴有神经丝氨酸蛋白酶抑制剂 12 基因新突变的神经丝包涵体脑神经病,表现为进行性肌阵挛癫痫。
Brain Pathol. 2011 Sep;21(5):575-82. doi: 10.1111/j.1750-3639.2011.00481.x. Epub 2011 Mar 24.
6
Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1.尿激酶型纤溶酶原激活物与其抑制剂-1 识别的结构基础。
J Biol Chem. 2011 Mar 4;286(9):7027-32. doi: 10.1074/jbc.M110.204537. Epub 2011 Jan 3.
7
Transgenic overexpression of a stable Plasminogen Activator Inhibitor-1 variant.稳定型纤溶酶原激活物抑制剂-1变体的转基因过表达
Thromb Res. 2009 Mar;123(5):785-92. doi: 10.1016/j.thromres.2008.07.004. Epub 2008 Sep 5.
8
Plasminogen activator inhibitor-1 is an inhibitor of factor VII-activating protease in patients with acute respiratory distress syndrome.纤溶酶原激活物抑制剂-1是急性呼吸窘迫综合征患者中因子VII激活蛋白酶的抑制剂。
J Biol Chem. 2007 Jul 27;282(30):21671-82. doi: 10.1074/jbc.M610748200. Epub 2007 May 31.
9
Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases.纤溶酶原激活物抑制剂-1的远端铰链区涉及其潜伏态转变以及对丝氨酸蛋白酶的特异性。
BMC Biochem. 2003 Jul 8;4:5. doi: 10.1186/1471-2091-4-5.
10
Familial encephalopathy with neuroserpin inclusion bodies.伴有神经丝氨酸蛋白酶包涵体的家族性脑病
Am J Pathol. 1999 Dec;155(6):1901-13. doi: 10.1016/S0002-9440(10)65510-1.